Business Wire

Mary Kay Inc. Earns Several Awards for Work in Business, COVID-19 Response and Sustainability Efforts

11.8.2021 16:03:00 EEST | Business Wire | Press release

Share

In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe, manufacturing irresistible products and building healthier, more sustainable communities even in response to COVID-19. In recognition of Mary Kay’s achievements in the last six months, the brand has taken home several coveted awards in the business, corporate citizenship, and leadership categories from various prestigious organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005163/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mary Kay was named a Silver Globee® Winner in 3 categories at the 13th Annual 2021 Golden Bridge Business and Innovation Awards. (Graphic: Mary Kay Inc.)

The awards, which range from recognition of the brand’s COVID-19 response to accolades for a Mary Kay-produced documentary on the Gulf of Mexico’s preservation efforts, highlight the company’s unwavering business values and its dedication to the principles defined by the brand’s legendary founder, Mary Kay Ash.

Latest awards include:

COVID-19 Response Awards

  • Silver Globee® Winner – 13th Annual 2021 Golden Bridge Business and Innovation Awards
    • Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
    • Company Response of the Year (Mary Kay Inc.)
    • Best Product To Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
  • Gold Globee® Winner – 13th Annual 2021 Golden Bridge Business and Innovation Awards
    • Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
  • Silver Globee® Winner – 6th Annual 2021 American Best in Business Awards
    • Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
    • Company Response of the Year (Mary Kay Inc.)
    • Best Product to Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
  • Gold Globee® Winner – 6th Annual 2021 American Best in Business Awards
    • Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)

Company Awards

  • America's Best Mid-Sized Employers 2021 – Forbes
  • “Power of Woman” Award, Mary Kay Ukraine, joint project with Marie Claire - X-RAY Marketing Awards
  • The Best Employer 2021, Mary Kay Poland – The Financial Magazine
  • Direct Sales Cosmetic Company Number One Award,Mary Kay Belarus – “Number One” Annual National Awards

Sustainability Awards

Guardians of the Gulf, an eye-opening documentary that explores the tumultuous relationship between the Gulf of Mexico and the conservationists determined to protect it, has received various awards. Mary Kay Inc., serving as executive producer, with Media One in partnership with The Nature Conservancy, visited the coasts of Texas, Alabama and Mexico to shed light on the often-untold stories of Gulf preservation.

  • Silver: Non-Broadcast General-Nature/Wildlife – Telly Awards
  • Bronze: Non-Broadcast General-Documentary – Telly Awards
  • Best Special Focus Documentary Finalist – LA Femme International Film Festival
  • World Remi Award – Worldfest Houston International Film Festival

Leadership Recognition

  • “67 Powerful Black Women CEOs And Executives In Corporate America,” Julia Simon, Chief Legal Officer and Corporate Secretary / Sheryl Adkins-Green, Chief Marketing Officer – Business Insider
  • “TOP Women CEOs in Ukraine” in Women’s Leadership in the Corporate Sector and Business rating - Viktoriia Zoria-Iatsenko, General Manager, Mary Kay Ukraine – WoMo (The Portal for Working Women)
  • “50 Most Valuable Women in Poland,” Ewa Kudlińska-Pyrz, General Manager, Mary Kay Poland – The Financial Magazine
  • “The Top 100 Women Leaders In Consumer Products Of 2021,” Allyson Sellers, Vice President of Sales, Mary Kay U.S. – Women We Admire

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye